The legislation in place today for regulating in silico products actually predates the existence of these technologies. In order for the in silco market to grow and for research in this field to be encouraged, a policy framework for in silico medicine needs to be developed. Just as the internet has created an urgent need to reform how we think about issues such as data security and IPR, in silico medicine requires we reevaluate our existing health policy structures. 

Even the most advanced and predictive model has little value to industry if it cannot be submitted as evidence of the effectiveness or safety of their product:

  • Manufacturers of medical devices who use in silico technologies must be provided with a framework for submitting this data to notified bodies, health authorities and evaluators of health technologies. 
  • Similarly for pharmaceuticals, a framework for admissibility of in silico clinical trial data needs to be developed so that we can move from exploratory clinical trials in humans, to a scenario where we seek to confirm what we know from in silico methods. 

 Incentives in policy need to be provided for industries that pioneer this research which has the potentially to drastically decrease overall research costs and greatly improve patient safety. Providing a system for assessing modelling and simulation data that supplement efficacy or safety data is required to bring healthcare into the digital era. 

“If healthcare is to move into the digital era, we need new policies that will enable this transition”

Avicenna Alliance news

The EESC calls for the creation of Good Simulation Practices

The European Economic and Social Affairs Committee (EESC) has specifically called for the creation of Good Simulation Practices as part...

find out more ›

Avicenna continues to grow by welcoming Altair among its members!

The Avicenna Alliance is proud to announce the newest addition to its list of members: Altair!

Altair is a global technology...

find out more ›

Avicenna provides feedback on the processing of personal health data in the EU

During the month of July, the Avicenna Alliance received the opportunity to provide its contribution to the European...

find out more ›

The European Medicines Agency has accepted the Avicenna Alliance's request to be directly involved in Agency activities

We are proud to announce that the European Medicines Agency (EMA) has accepted...

find out more ›

The Avicenna Alliance provided feedback on the Pharmaceutical Strategy for Europe

We are proud to announce that the Avicenna Alliance has submitted Members’ feedback to the European Commission’s...

find out more ›

Show all activites

Sign up for our monthly newsletter!


Sign up